Search

Your search keyword '"Yamaguchi, Kensei"' showing total 93 results
Start Over Author "Yamaguchi, Kensei" Publisher american association for cancer research (aacr)
93 results on '"Yamaguchi, Kensei"'

1. Pharmacological targeting of histone H3K27 acetylation/BRD4-dependent induction of ALDH1A3 for early-phase drug tolerance of gastric cancer

Author

Lee, Jin, primary, Mashima, Tetsuo, additional, Kawata, Naomi, additional, Yamamoto, Noriko, additional, Morino, Shun, additional, Inaba, Saori, additional, Nakamura, Ayane, additional, Kumagai, Koshi, additional, Wakatsuki, Takeru, additional, Takeuchi, Kengo, additional, Yamaguchi, Kensei, additional, and Seimiya, Hiroyuki, additional

Published
2024
Full Text
View/download PDF

2. Supplementary Table S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

3. Supplementary Figure S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

4. Supplementary Figure S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

5. Supplementary Table S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

6. Supplementary Table S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

7. Supplementary Figure S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

8. Supplementary Table S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

9. Data from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

10. Supplementary Table S5 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

11. Supplementary Table S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

12. Supplementary Table S4 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

13. Supplementary Figure S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

14. Supplementary Figure S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

15. Supplementary Table S4 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

16. Data from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

17. Supplementary Table S5 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

18. Supplementary Table S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

19. Supplementary Figure S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

20. Phase 2 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, additional, Sugimoto, Naotoshi, additional, Kawakami, Hisato, additional, Oshima, Takashi, additional, Yamaguchi, Kensei, additional, Hino, Kaori, additional, Hirao, Motohiro, additional, Kurokawa, Yukinori, additional, Kawakami, Takeshi, additional, Tsuda, Masahiro, additional, Hara, Hiroki, additional, Kaname, Shota, additional, Matsuoka, Daiko, additional, Otake, Yohei, additional, Yasuda, Keisuke, additional, Takase, Takao, additional, Takashima, Shuya, additional, Semba, Taro, additional, and Muro, Kei, additional

Published
2024
Full Text
View/download PDF

21. Supplementary Figure S5 from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort

Author

Shitara, Kohei, primary, Hirao, Motohiro, primary, Iwasa, Satoru, primary, Oshima, Takashi, primary, Komatsu, Yoshito, primary, Kawazoe, Akihito, primary, Sato, Yasuyoshi, primary, Hamakawa, Takuya, primary, Yonemori, Kan, primary, Machida, Nozomu, primary, Yuki, Satoshi, primary, Suzuki, Takuya, primary, Okumura, Shiori, primary, Takase, Takao, primary, Semba, Taro, primary, Zimmermann, Bob, primary, Teng, Angela, primary, and Yamaguchi, Kensei, primary

Published
2023
Full Text
View/download PDF

22. Abstract CT037: Nivolumab plus ipilimumab vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: CheckMate 649 biomarker analyses

Author

Janjigian, Yelena Y., primary, Shitara, Kohei, additional, Ajani, Jaffer, additional, Moehler, Markus, additional, Yao, Jin, additional, Shen, Lin, additional, Garrido, Marcelo, additional, Gallardo, Carlos, additional, Wyrwicz, Lucjan, additional, Yamaguchi, Kensei, additional, Skoczylas, Tomasz, additional, Bragagnoli, Arinilda, additional, Liu, Tianshu, additional, Schenker, Michael, additional, Yañez, Patricio, additional, Kowalyszyn, Ruben, additional, Karamouzis, Michalis, additional, Zander, Thomas, additional, Feeney, Kynan, additional, Elimova, Elena, additional, Nathani, Raheel, additional, Novosiadly, Ruslan, additional, and Lei, Ming, additional

Published
2023
Full Text
View/download PDF

23. Supplementary Table S1 from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort

Author

Shitara, Kohei, primary, Hirao, Motohiro, primary, Iwasa, Satoru, primary, Oshima, Takashi, primary, Komatsu, Yoshito, primary, Kawazoe, Akihito, primary, Sato, Yasuyoshi, primary, Hamakawa, Takuya, primary, Yonemori, Kan, primary, Machida, Nozomu, primary, Yuki, Satoshi, primary, Suzuki, Takuya, primary, Okumura, Shiori, primary, Takase, Takao, primary, Semba, Taro, primary, Zimmermann, Bob, primary, Teng, Angela, primary, and Yamaguchi, Kensei, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Table S4 from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort

Author

Shitara, Kohei, primary, Hirao, Motohiro, primary, Iwasa, Satoru, primary, Oshima, Takashi, primary, Komatsu, Yoshito, primary, Kawazoe, Akihito, primary, Sato, Yasuyoshi, primary, Hamakawa, Takuya, primary, Yonemori, Kan, primary, Machida, Nozomu, primary, Yuki, Satoshi, primary, Suzuki, Takuya, primary, Okumura, Shiori, primary, Takase, Takao, primary, Semba, Taro, primary, Zimmermann, Bob, primary, Teng, Angela, primary, and Yamaguchi, Kensei, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Table S2 from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort

Author

Shitara, Kohei, primary, Hirao, Motohiro, primary, Iwasa, Satoru, primary, Oshima, Takashi, primary, Komatsu, Yoshito, primary, Kawazoe, Akihito, primary, Sato, Yasuyoshi, primary, Hamakawa, Takuya, primary, Yonemori, Kan, primary, Machida, Nozomu, primary, Yuki, Satoshi, primary, Suzuki, Takuya, primary, Okumura, Shiori, primary, Takase, Takao, primary, Semba, Taro, primary, Zimmermann, Bob, primary, Teng, Angela, primary, and Yamaguchi, Kensei, primary

Published
2023
Full Text
View/download PDF

26. Data from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort

Author

Shitara, Kohei, primary, Hirao, Motohiro, primary, Iwasa, Satoru, primary, Oshima, Takashi, primary, Komatsu, Yoshito, primary, Kawazoe, Akihito, primary, Sato, Yasuyoshi, primary, Hamakawa, Takuya, primary, Yonemori, Kan, primary, Machida, Nozomu, primary, Yuki, Satoshi, primary, Suzuki, Takuya, primary, Okumura, Shiori, primary, Takase, Takao, primary, Semba, Taro, primary, Zimmermann, Bob, primary, Teng, Angela, primary, and Yamaguchi, Kensei, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Table S1 from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort

Author

Shitara, Kohei, primary, Hirao, Motohiro, primary, Iwasa, Satoru, primary, Oshima, Takashi, primary, Komatsu, Yoshito, primary, Kawazoe, Akihito, primary, Sato, Yasuyoshi, primary, Hamakawa, Takuya, primary, Yonemori, Kan, primary, Machida, Nozomu, primary, Yuki, Satoshi, primary, Suzuki, Takuya, primary, Okumura, Shiori, primary, Takase, Takao, primary, Semba, Taro, primary, Zimmermann, Bob, primary, Teng, Angela, primary, and Yamaguchi, Kensei, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure S2 from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort

Author

Shitara, Kohei, primary, Hirao, Motohiro, primary, Iwasa, Satoru, primary, Oshima, Takashi, primary, Komatsu, Yoshito, primary, Kawazoe, Akihito, primary, Sato, Yasuyoshi, primary, Hamakawa, Takuya, primary, Yonemori, Kan, primary, Machida, Nozomu, primary, Yuki, Satoshi, primary, Suzuki, Takuya, primary, Okumura, Shiori, primary, Takase, Takao, primary, Semba, Taro, primary, Zimmermann, Bob, primary, Teng, Angela, primary, and Yamaguchi, Kensei, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figure S2 from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort

Author

Shitara, Kohei, primary, Hirao, Motohiro, primary, Iwasa, Satoru, primary, Oshima, Takashi, primary, Komatsu, Yoshito, primary, Kawazoe, Akihito, primary, Sato, Yasuyoshi, primary, Hamakawa, Takuya, primary, Yonemori, Kan, primary, Machida, Nozomu, primary, Yuki, Satoshi, primary, Suzuki, Takuya, primary, Okumura, Shiori, primary, Takase, Takao, primary, Semba, Taro, primary, Zimmermann, Bob, primary, Teng, Angela, primary, and Yamaguchi, Kensei, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figure S4 from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort

Author

Shitara, Kohei, primary, Hirao, Motohiro, primary, Iwasa, Satoru, primary, Oshima, Takashi, primary, Komatsu, Yoshito, primary, Kawazoe, Akihito, primary, Sato, Yasuyoshi, primary, Hamakawa, Takuya, primary, Yonemori, Kan, primary, Machida, Nozomu, primary, Yuki, Satoshi, primary, Suzuki, Takuya, primary, Okumura, Shiori, primary, Takase, Takao, primary, Semba, Taro, primary, Zimmermann, Bob, primary, Teng, Angela, primary, and Yamaguchi, Kensei, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Figure S4 from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort

Author

Shitara, Kohei, primary, Hirao, Motohiro, primary, Iwasa, Satoru, primary, Oshima, Takashi, primary, Komatsu, Yoshito, primary, Kawazoe, Akihito, primary, Sato, Yasuyoshi, primary, Hamakawa, Takuya, primary, Yonemori, Kan, primary, Machida, Nozomu, primary, Yuki, Satoshi, primary, Suzuki, Takuya, primary, Okumura, Shiori, primary, Takase, Takao, primary, Semba, Taro, primary, Zimmermann, Bob, primary, Teng, Angela, primary, and Yamaguchi, Kensei, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Table S3 from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort

Author

Shitara, Kohei, primary, Hirao, Motohiro, primary, Iwasa, Satoru, primary, Oshima, Takashi, primary, Komatsu, Yoshito, primary, Kawazoe, Akihito, primary, Sato, Yasuyoshi, primary, Hamakawa, Takuya, primary, Yonemori, Kan, primary, Machida, Nozomu, primary, Yuki, Satoshi, primary, Suzuki, Takuya, primary, Okumura, Shiori, primary, Takase, Takao, primary, Semba, Taro, primary, Zimmermann, Bob, primary, Teng, Angela, primary, and Yamaguchi, Kensei, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure S3 from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort

Author

Shitara, Kohei, primary, Hirao, Motohiro, primary, Iwasa, Satoru, primary, Oshima, Takashi, primary, Komatsu, Yoshito, primary, Kawazoe, Akihito, primary, Sato, Yasuyoshi, primary, Hamakawa, Takuya, primary, Yonemori, Kan, primary, Machida, Nozomu, primary, Yuki, Satoshi, primary, Suzuki, Takuya, primary, Okumura, Shiori, primary, Takase, Takao, primary, Semba, Taro, primary, Zimmermann, Bob, primary, Teng, Angela, primary, and Yamaguchi, Kensei, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Table S2 from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort

Author

Shitara, Kohei, primary, Hirao, Motohiro, primary, Iwasa, Satoru, primary, Oshima, Takashi, primary, Komatsu, Yoshito, primary, Kawazoe, Akihito, primary, Sato, Yasuyoshi, primary, Hamakawa, Takuya, primary, Yonemori, Kan, primary, Machida, Nozomu, primary, Yuki, Satoshi, primary, Suzuki, Takuya, primary, Okumura, Shiori, primary, Takase, Takao, primary, Semba, Taro, primary, Zimmermann, Bob, primary, Teng, Angela, primary, and Yamaguchi, Kensei, primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure S5 from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort

Author

Shitara, Kohei, primary, Hirao, Motohiro, primary, Iwasa, Satoru, primary, Oshima, Takashi, primary, Komatsu, Yoshito, primary, Kawazoe, Akihito, primary, Sato, Yasuyoshi, primary, Hamakawa, Takuya, primary, Yonemori, Kan, primary, Machida, Nozomu, primary, Yuki, Satoshi, primary, Suzuki, Takuya, primary, Okumura, Shiori, primary, Takase, Takao, primary, Semba, Taro, primary, Zimmermann, Bob, primary, Teng, Angela, primary, and Yamaguchi, Kensei, primary

Published
2023
Full Text
View/download PDF

36. Data from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort

Author

Shitara, Kohei, primary, Hirao, Motohiro, primary, Iwasa, Satoru, primary, Oshima, Takashi, primary, Komatsu, Yoshito, primary, Kawazoe, Akihito, primary, Sato, Yasuyoshi, primary, Hamakawa, Takuya, primary, Yonemori, Kan, primary, Machida, Nozomu, primary, Yuki, Satoshi, primary, Suzuki, Takuya, primary, Okumura, Shiori, primary, Takase, Takao, primary, Semba, Taro, primary, Zimmermann, Bob, primary, Teng, Angela, primary, and Yamaguchi, Kensei, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure S1 from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort

Author

Shitara, Kohei, primary, Hirao, Motohiro, primary, Iwasa, Satoru, primary, Oshima, Takashi, primary, Komatsu, Yoshito, primary, Kawazoe, Akihito, primary, Sato, Yasuyoshi, primary, Hamakawa, Takuya, primary, Yonemori, Kan, primary, Machida, Nozomu, primary, Yuki, Satoshi, primary, Suzuki, Takuya, primary, Okumura, Shiori, primary, Takase, Takao, primary, Semba, Taro, primary, Zimmermann, Bob, primary, Teng, Angela, primary, and Yamaguchi, Kensei, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Table S4 from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort

Author

Shitara, Kohei, primary, Hirao, Motohiro, primary, Iwasa, Satoru, primary, Oshima, Takashi, primary, Komatsu, Yoshito, primary, Kawazoe, Akihito, primary, Sato, Yasuyoshi, primary, Hamakawa, Takuya, primary, Yonemori, Kan, primary, Machida, Nozomu, primary, Yuki, Satoshi, primary, Suzuki, Takuya, primary, Okumura, Shiori, primary, Takase, Takao, primary, Semba, Taro, primary, Zimmermann, Bob, primary, Teng, Angela, primary, and Yamaguchi, Kensei, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure S3 from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort

Author

Shitara, Kohei, primary, Hirao, Motohiro, primary, Iwasa, Satoru, primary, Oshima, Takashi, primary, Komatsu, Yoshito, primary, Kawazoe, Akihito, primary, Sato, Yasuyoshi, primary, Hamakawa, Takuya, primary, Yonemori, Kan, primary, Machida, Nozomu, primary, Yuki, Satoshi, primary, Suzuki, Takuya, primary, Okumura, Shiori, primary, Takase, Takao, primary, Semba, Taro, primary, Zimmermann, Bob, primary, Teng, Angela, primary, and Yamaguchi, Kensei, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Figure S1 from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort

Author

Shitara, Kohei, primary, Hirao, Motohiro, primary, Iwasa, Satoru, primary, Oshima, Takashi, primary, Komatsu, Yoshito, primary, Kawazoe, Akihito, primary, Sato, Yasuyoshi, primary, Hamakawa, Takuya, primary, Yonemori, Kan, primary, Machida, Nozomu, primary, Yuki, Satoshi, primary, Suzuki, Takuya, primary, Okumura, Shiori, primary, Takase, Takao, primary, Semba, Taro, primary, Zimmermann, Bob, primary, Teng, Angela, primary, and Yamaguchi, Kensei, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Table S3 from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort

Author

Shitara, Kohei, primary, Hirao, Motohiro, primary, Iwasa, Satoru, primary, Oshima, Takashi, primary, Komatsu, Yoshito, primary, Kawazoe, Akihito, primary, Sato, Yasuyoshi, primary, Hamakawa, Takuya, primary, Yonemori, Kan, primary, Machida, Nozomu, primary, Yuki, Satoshi, primary, Suzuki, Takuya, primary, Okumura, Shiori, primary, Takase, Takao, primary, Semba, Taro, primary, Zimmermann, Bob, primary, Teng, Angela, primary, and Yamaguchi, Kensei, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results